FDA Accepts Jazz Pharmaceuticals’ NDA for Solriamfetol Treatment in Patients with Narcolepsy and Sleep Apnea
On March 2, Jazz Pharmaceuticals plc (JAZZ) announced that the FDA has accepted the company’s filing of a New Drug Application (NDA) with standard review for market approval of Solriamfetol. The drug is an investigational medicine used for the treatment of excessive sleepiness in patients with narcolepsy and obstructive sleep apnea (OSA). The company hopes to have an FDA decision by December 20.
Rocket Tickers detected the event and sent an alert to subscribers at 8:30 am. The next trade was at 9:05 am for $141. The market opened for regular market trading at $140.38. The stock closed higher on the day of the announcement and continued to rise over the next five trading sessions. Jazz Pharmaceuticals closed at $152.31 on March 9 for a gain of 8% in the week after the announcement.
Visit the Knowledge Center for more information about clinical trials and how to trade them.
Check out our latest Live Webinar which provides more information about price patterns after clinical trial announcements and how to trade them.
Subscribe here if you would like to start receiving these signals in real-time and start trading!